How do you approach missed doses of durvalumab consolidation in patients with Stage III NSCLC?

This is a common topic that comes up in clinic. In a previous question, the discussion centered around when/if to resume durvalumab if treatment was held due to toxicity. Here, I assume missed doses occurred for non-irAE reasons. Personally, I discontinue treatment at the completion of 1 year of the...